DEPO-TESTOSTERONE INJ 100MG/ML SOLUTION

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Kupi sada

Svojstava lijeka Svojstava lijeka (SPC)
12-07-2018

Aktivni sastojci:

TESTOSTERONE CYPIONATE

Dostupno od:

PFIZER CANADA ULC

ATC koda:

G03BA03

INN (International ime):

TESTOSTERONE

Doziranje:

100MG

Farmaceutski oblik:

SOLUTION

Sastav:

TESTOSTERONE CYPIONATE 100MG

Administracija rute:

INTRAMUSCULAR

Jedinice u paketu:

10ML

Tip recepta:

Schedule G (CDSA IV)

Područje terapije:

ANDROGENS

Proizvod sažetak:

Active ingredient group (AIG) number: 0106401001; AHFS:

Status autorizacije:

APPROVED

Datum autorizacije:

2001-06-04

Svojstava lijeka

                                _ _
_DEPO-TESTOSTERONE Product Monograph _
_ _
_Page 1 of 20_
PRODUCT MONOGRAPH
DEPO-TESTOSTERONE
testosterone cypionate injection
100 mg/mL sterile solution
USP
Androgens
Pfizer Canada Inc.
17, 300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Date of Revision:
July 12, 2018
Submission Control No: 217239
©
Pfizer Canada Inc., 2018
_ _
_DEPO-TESTOSTERONE Product Monograph _
_Page 2 of 20 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND STABILITY
..........................................................................................13
SPECIAL HANDLING INSTRUCTIONS
.......................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................15
PHARMACEUTICAL INFO
                                
                                Pročitajte cijeli dokument
                                
                            

Dokumenti na drugim jezicima

Svojstava lijeka Svojstava lijeka francuski 12-07-2018

Upozorenja za pretraživanje vezana za ovaj proizvod